On October 27, CANSINOBIO fell 5.1% intraday in regular trading, trading at HK$27.5, with turnover of HK$39.92 million.

The move was linked to weaker market sentiment toward the mRNA theme after previously anticipated overseas clinical data for a cancer vaccine came in below elevated expectations.

Background context shows that data from the Phase III trial of Moderna and Merck’s personalized melanoma vaccine was disclosed earlier than expected and failed to meet the market’s high bar, pressuring related concept stocks. CANSINOBIO has built an mRNA development and manufacturing platform and previously entered a framework agreement with a partner to co-develop a personalized mRNA cancer vaccine. The company had also noted earlier that the release of overseas mRNA oncology vaccine milestone data could affect share-price volatility.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)